Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26718859 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL15498659 | 0.89 | POLB (0.43) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL8224831 | 0.86 | ALDH1A1 (0.41) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL11206123 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL21661624 | 0.81 | POLB (0.38) | ALDH1A1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL11197967 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL20988155 | 0.78 | ALDH1A1 (0.48) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL11813285 | 0.77 | ALDH1A1 (0.47) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL14673052 | 0.76 | POLB (0.50) | ALDH1A1MAPTPOLBSMN1; SMN2GAA | |
| SCHEMBL21870591 | 0.75 | ALDH1A1 (0.48) | ALDH1A1MAPTPOLBSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | ATHOS THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11141406-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-10-12 | — | — | US | disclosed |
| US-11078189-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-10-08 | — | — | US | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | SILICON VALLEY BANK | 2020-06-04 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-03-10 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-7691879-B2 | Isoquinoline potassium channel inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-4374040-A | ANTICORROSION, ANTISCALE, ANTIDERPOSIT | BUCKMAN LABORATORIES, INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4243524-A | ANTISCALING, ANTISLUDGING | BUCKMAN LABORATORIES, INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4181806-A | ANTISLUDGING AGENTS, ANTISCALING AGENTS | BUCKMAN LABORATORIES, INC. (US) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | ALDH1A1 1403/4885MAPT 3991/4885POLB 81/4885 |
| US-11141406-B2 | Pharmaceutical compounds | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | ALDH1A1 3355/4885MAPT 4010/4885POLB 2709/4885 |
| US-20210047328-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | TYMP, TYMS, DPYD | ALDH1A1 1403/4885MAPT 3991/4885POLB 81/4885 |
| US-20110059943-A1 | JAK2 INHIBITORS AND THEIR USE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND CANCER | JAK2, JAK1, JAK3 | ALDH1A1 2563/4885MAPT 4836/4885POLB 2432/4885 |
| US-20230159498-A1 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | SSB, HLA-DRB1, UACA | ALDH1A1 3670/4885MAPT 4698/4885POLB 1646/4885 |
| US-20200316030-A1 | PHARMACEUTICAL COMPOUNDS | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1 | ALDH1A1 3435/4885MAPT 4099/4885POLB 2798/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | ALDH1A1 574/4885MAPT 4144/4885POLB 132/4885 |
| US-11078189-B2 | Pharmaceutical compounds | HRH4, CHRM5, CHRM1 | ALDH1A1 3367/4885MAPT 3311/4885POLB 3491/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | ALDH1A1 911/4885MAPT 3328/4885POLB 76/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | ALDH1A1 1556/4885MAPT 45/4885POLB 9/4885 |
| US-20200172515-A1 | PHARMACEUTICAL COMPOUNDS | HRH4, CHRM5, CHRM1 | ALDH1A1 3367/4885MAPT 3311/4885POLB 3491/4885 |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | ALDH1A1 1348/4885MAPT 3455/4885POLB 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.